Myelodysplastic syndromes, version 2.2017: Clinical practice guidelines in oncology

Peter L. Greenberg, Richard M. Stone, Aref Al-Kali, Stefan K. Barta, Rafael Bejar, John M. Bennett, Hetty Carraway, Carlos M. De Castro, H. Joachim Deeg, Amy E. DeZern, Amir T. Fathi, Olga Frankfurt, Karin Gaensler, Guillermo Garcia-Manero, Elizabeth A. Griffiths, David Head, Ruth Horsfall, Robert A. Johnson, Mark Juckett, Virginia M. KlimekRami Komrokji, Lisa A. Kujawski, Lori J Maness-Harris, Margaret R. O'Donnell, Daniel A. Pollyea, Paul J. Shami, Brady L. Stein, Alison R. Walker, Peter Westervelt, Amer Zeidan, Dorothy A. Shead, Courtney Smith

Research output: Contribution to journalReview article

103 Scopus citations


The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid disorders with a highly variable disease course. Diagnostic criteria to better stratify patients with MDS continue to evolve, based on morphology, cytogenetics, and the presence of cytopenias. More accurate classification of patients will allow for better treatment guidance. Treatment encompasses supportive care, treatment of anemia, lowintensity therapy, and high-intensity therapy. This portion of the guidelines focuses on diagnostic classification, molecular abnormalities, therapeutic options, and recommended treatment approaches.

Original languageEnglish (US)
Pages (from-to)60-87
Number of pages28
JournalJNCCN Journal of the National Comprehensive Cancer Network
Issue number1
StatePublished - Jan 1 2017


ASJC Scopus subject areas

  • Oncology

Cite this

Greenberg, P. L., Stone, R. M., Al-Kali, A., Barta, S. K., Bejar, R., Bennett, J. M., Carraway, H., De Castro, C. M., Deeg, H. J., DeZern, A. E., Fathi, A. T., Frankfurt, O., Gaensler, K., Garcia-Manero, G., Griffiths, E. A., Head, D., Horsfall, R., Johnson, R. A., Juckett, M., ... Smith, C. (2017). Myelodysplastic syndromes, version 2.2017: Clinical practice guidelines in oncology. JNCCN Journal of the National Comprehensive Cancer Network, 15(1), 60-87.